Robert L. Coleman, MD
Professor & Vice Chair, Clinical Research
The University of Texas MD Anderson Cancer Center
Unit 1362 P.O. Box 301439
Houston,
TX
USA
77230-1439
Biographical Sketch: Robert L. Coleman, MD is professor of gynecologic oncology and Vice-Chair, Clinical Research at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr Coleman received his doctor of medicine degree from Creighton University in Omaha, Nebraska and completed his obstetrics/gynecology residency at Northwestern University Medical Center in Chicago, Illinois; he completed his fellowship at The University of Texas MD Anderson Cancer Center. Dr Coleman’s research interests include novel therapeutics for ovarian, uterine, and cervical cancer, clinical trial development and statistical design, surgical innovations, and graduate education. He is MDACC’s Gynecologic Oncology Group (GOG) principal investigator (PI), serves on the GOG’s Ovarian and Developmental Therapeutics Committees, and is PI or co-PI for several GOG prospective clinical trials. He currently is a co-project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, the Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers. He is also funded by CPRIT to conduct a first-in-human trial of a systemically delivered siRNA product for gene silencing in solid tumors. Dr Coleman has authored or coauthored over 400 scientific publications, including over 180 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and Atlas of Gynecologic Oncology. Dr Coleman has served as a member of the Board of Directors for the Foundation for Women’s Cancer (formerly, the Gynecologic Cancer Foundation) and serves on the Council of the Society of Gynecologic Oncologists and on the Division of Gynecologic Oncology in ABOG. In June 2010 he was appointed to the Ann Rife Cox Chair in Gynecology."
Papers:
14
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study sub-analysis
20
Personalized surgical therapy for advanced ovarian cancer
46
Homologous recombination deficiency in uterine cancer
134
The FAK of uterine cancer: PTEN expression predicts response of uterine cancer to focal adhesion kinase inhibition
135
Molecular predictors of response to EphA2 targeted therapy in uterine cancer
155
Fuel for the fire: connecting genomics with metabolomics in ovarian cancer
192
Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
355
Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study
421
Identifying therapeutic options in small cell cervical cancer by multiplatform evaluation of biomarker alterations
Panel Discussion - Monk
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian
Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: interim results for ARIEL2 clinical trial
Announcment of IMPROVING OUTCOMES IN GYNECOLOGIC ONCOLOGY PATIENTS RESEARCH AND EDUCATION AWARD, ME STRONG YOUNG INVESTIGATOR’S AWARD, SGO FELLOW-IN-TRAINING OVARIAN CANCER AWARD, WILMA WILLIAMS EDUCATION AND CLINICAL RESEARCH AWARD FOR ENDOMETRIAL CANCER
Introductory Remarks